Evidence map›Paper›PMID 36384931›Full record

ArticleNature communications2022

Increased slow dynamics defines ligandability of BTB domains.

Vladlena Kharchenko, Brian M Linhares, Megan Borregard, Iwona Czaban, Jolanta Grembecka, Mariusz Jaremko, Tomasz Cierpicki, Łukasz Jaremko

Abstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pitfalls in measurements of RJournal of biomolecular NMR · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vladlena Kharchenko *Smart Health Initiative (SHI), Red Sea Research Center (RSRC), Bioscience Program, Biological and Environmental Science & Engineering (BESE), King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.
Brian M Linhares *Department of Pathology, University of Michigan, 1150 West Medical Center Dr, MSRB I, Room 4510D, Ann Arbor, MI, 48108, USA.
Megan BorregardDepartment of Pathology, University of Michigan, 1150 West Medical Center Dr, MSRB I, Room 4510D, Ann Arbor, MI, 48108, USA.
Iwona CzabanSmart Health Initiative (SHI), Red Sea Research Center (RSRC), Bioscience Program, Biological and Environmental Science & Engineering (BESE), King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.ORCID 0000-0002-8038-1573
Jolanta GrembeckaDepartment of Pathology, University of Michigan, 1150 West Medical Center Dr, MSRB I, Room 4510D, Ann Arbor, MI, 48108, USA.ORCID 0000-0002-6180-9095
Mariusz JaremkoSmart Health Initiative (SHI), Red Sea Research Center (RSRC), Bioscience Program, Biological and Environmental Science & Engineering (BESE), King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia.
Tomasz CierpickiDepartment of Pathology, University of Michigan, 1150 West Medical Center Dr, MSRB I, Room 4510D, Ann Arbor, MI, 48108, USA. tomaszc@umich.edu.ORCID 0000-0003-2058-0658
Łukasz JaremkoSmart Health Initiative (SHI), Red Sea Research Center (RSRC), Bioscience Program, Biological and Environmental Science & Engineering (BESE), King Abdullah University of Science and Technology (KAUST), 23955-6900, Thuwal, Saudi Arabia. lukasz.jaremko@kaust.edu.sa.ORCID 0000-0001-7684-9359

Funding

Development of small molecules targeting Ring1B-Bmi1 E3 ligase in leukemiaR01CA207272 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CIERPICKI, TOMASZ · 2016 to 2020
$2.0M
NCI NIH HHS R01 CA207272
6 · The paper itself

Abstract

Efficient determination of protein ligandability, or the propensity to bind small-molecules, would greatly facilitate drug development for novel targets. Ligandability is currently assessed using computational methods that typically consider the static structural properties of putative binding sites or by experimental fragment screening. Here, we evaluate ligandability of conserved BTB domains from the cancer-relevant proteins LRF, KAISO, and MIZ1. Using fragment screening, we discover that MIZ1 binds multiple ligands. However, no ligands are uncovered for the structurally related KAISO or LRF. To understand the principles governing ligand-binding by BTB domains, we perform comprehensive NMR-based dynamics studies and find that only the MIZ1 BTB domain exhibits backbone µs-ms time scale motions. Interestingly, residues with elevated dynamics correspond to the binding site of fragment hits and recently defined HUWE1 interaction site. Our data argue that examining protein dynamics using NMR can contribute to identification of cryptic binding sites, and may support prediction of the ligandability of novel challenging targets.

Indexed as

BTB-POZ DomainBinding SitesLigandsProtein BindingProteinsLigandsProteins

Identifiers

PMID36384931
PMCPMC9668832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.